Elixir Medical Corporation
18
1
4
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
11.1%
2 terminated/withdrawn out of 18 trials
84.6%
-1.9% vs industry average
6%
1 trials in Phase 3/4
36%
4 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System
Role: lead
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
Role: lead
A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter
Role: lead
DynamX Bioadaptor Hong Kong Registry
Role: lead
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
Role: lead
The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
Role: lead
DESyne X2 Post Market Follow-up Study
Role: lead
DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions
Role: lead
Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial
Role: lead
Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial
Role: lead
Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study
Role: lead
Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry
Role: lead
The DESappear Study: Drug Eluting Scaffold
Role: lead
DESolve® X-Pand Global Post Market Registry
Role: lead
EXCELLA Post-Approval Study
Role: lead
DynamX Sirolimus Study Sirolimus Eluting Coronary Bioadaptor System
Role: lead
Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"
Role: lead
DESolve Post-Approval Study
Role: lead
All 18 trials loaded